Key clinical point: Preventive treatment with vigabatrin reduces the risk and severity of epilepsy in patients with tuberous sclerosis complex.

Major finding: In a randomized, controlled trial, time to first seizure was 364 days in patients who received preventive treatment and 124 days in patients who received conventional treatment.

Study details: An analysis of 53 participants with tuberous sclerosis complex in a randomized trial and 41 participants with tuberous sclerosis complex in an open-label trial.

Disclosures: The study was funded by the 7th Framework Program of the European Union.